Celcuity Stock Soars 14% to $143 on Positive Phase 3 Breast Cancer Trial Data

Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes

Celcuity Inc. shares rose nearly 16% Monday after reporting its breast cancer drug gedatolisib met the main goal in a late-stage trial for patients with PIK3CA-mutant tumors. The company plans to submit the new data to the FDA as a supplemental application. Celcuity traded at $145.54, up $19.89, with a market value near $6.9 billion. A July 17 FDA decision on gedatolisib for a related use remains pending. The post Celcuity Stock Jumps 16% as Ged…

Celcuity Stock Soars 14% to $143 on Positive Phase 3 Breast Cancer Trial Data

NEW YORK — Celcuity Inc. shares surged more than 13.8 percent to $143 in early trading Monday, May 4, 2026, after the clinical-stage oncology company announced that its Phase 3 VIKTORIA-1 trial met the primary endpoint with clinically meaningful improvement in progression-free survival for patients with PIK3CA-mutant advanced breast cancer.

Celcuity reports Phase III VIKTORIA-1 trial results for breast cancer

Celcuity has reported topline outcomes from the PIK3CA mutant cohort of the Phase III VIKTORIA-1 clinical trial assessing gedatolisib combined with fulvestrant, with or without palbociclib, in patients with breast cancer.The post Celcuity reports Phase III VIKTORIA-1 trial results for breast cancer appeared first on Hospital Management.

Celcuity’s Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

MINNEAPOLIS, May 01, 2026 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced positive topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with or without palbociclib in patients with hormone receptor positive (“HR+”), human epidermal […] The post Celcuity’s Phase …